Transcript focused on: real opportunity

FACT SHEET Q3 2005
LAB International Inc. (LAB)
FAST FACTS
TXS Symbol: LAB
Fiscal Year-End: December 31
Shares Outstanding: 70 million
Fully Diluted: 90 million
Year High-Low: $1.45 - $0.63
Market Capitalization: $75 million
Cash (Q3-05): $15 million
Website: labinc.ca
integrated
labinc.ca
LAB International (LAB Pharma and LAB Research) is an integrated drug development company with
subsidiaries focused on developing therapies for the inhalation market and on providing contract
research services. LAB Pharma’s lead product, for the treatment of breakthrough cancer pain, is a
fast-acting Fentanyl formulation delivered using the Company’s approved TAIFUN® dry powder
inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone
deficiencies. LAB Research is a profitable and growing research services division supporting LAB
Pharma’s drug development efforts while also serving its clients from state-of–the-art facilities in
Canada, the US, Denmark and Hungary.
focused on: real sustainability
LAB Pharma focuses
on the development of
novel therapeutics while leveraging the experience
and infrastructure of LAB Research. Recognizing the
potential of using its proprietary platforms to deliver its
own inhalation products as well as those of third
parties, LAB Pharma also operates as a drug delivery
company offering its leading regulatory approved
inhalation systems to the industry along with
formulation expertise and manufacturing capabilites.
LAB Research,
which began in 1998 as a
specialized contract research organization, is providing drug
development services to the pharmaceutical and
biotechnology industries. This division grew by 41% in 2003,
generating revenues of more than $15 million and $3 million
of EBITDA. For 2004, it generated $23,8 million in revenues,
and $5,75 million in EBITDA, increases of 60% and 57%
respectively over 2003. Year-to-date 2005, LAB Research
has generated $33.2 million in revenues and $7.6 million of
EBITDA, increases of 86% and 63%, respectively over 2004.
14
12
LAB Research Revenue
(since public)
10
$ Million
8
6
4
2
0
2002
focused on: real opportunity
2004
2005
Fully effective levels within 1 minute !
1200
Fentanyl TAIFUN®
Mean Plasma Concentration of Fentanyl (pg/ml)
1000
Concentration (pg/ml)
Even though persistent cancer pain is controlled with longacting formulations of the well-known analgesic Fentanyl, the
majority of cancer patients with chronic pain still experience
breakthrough pain, which is characterized by intermittent flares
of pain that ‘break through’ regular pain medication.
LAB is developing a fast-acting Fentanyl formulation to treat
breakthrough pain using its proprietary TAIFUN® inhalation
delivery platform. Inhalation is the fastest alternative to
intravenous administration and is painless. The rapid onset of
action (see chart on right) and ease of use of Fentanyl
TAIFUN® are clear advantages compared with oral,
transmucosal and injectable alternatives that currently service
the $1 billion breakthrough pain market.
2003
800
Fentanyl TAIFUN ® 200 mcg
600
Actiq ® 200 mcg
400
200
0
0
20
40
60
80
Time (min.)
100
120
140
focused on: real opportunity
The TAIFUN® inhaler platform can be applied to a wide range of therapeutics, both for
the treatment of disease of the lungs directly and for the rapid systemic delivery of
drugs throughout the body. LAB’s vision is to become a leading developer of dry
powder respiratory products, targeting a $15 billion inhalation market that is
undergoing tremendous growth and change as demonstrated amongst others by the
recent FDA committee approval for inhaled insulin (Exubera).
Systemic delivery
LAB Pharma’s current pipeline includes inhalation delivered therapeutics for asthma,
chronic renal failure and pain management.
Local delivery
Product Portfolio
Indication
Pre-clinical
Phase I
Phase II
Phase III
Market size ($)
Fentanyl TAIFUN®
breakthrough cancer pain
US $2 B.
CGRP
asthma
US $15 B.
GHRH
chronic renal failure
US $1 B.
LAB’s proprietary TAIFUN® inhaler is a regulatory approved, multiple dose, dry powder inhaler platform engineered to provide
highly efficient delivery of active drugs deep into the lung. More than ten years of experience and $80 million have been invested
into the development of TAIFUN®.
TAIFUN® has been peer reviewed and is considered best in class. It has demonstrated superior
clinical performance against competing inhalers and consistently delivers a uniform dose, independent
of flow-rate or humidity, making it the ideal platform for breathing impaired patients, children and the
elderly. The TAIFUN® inhaler has solid patent protection and has already been approved in Europe for
the delivery of the asthma drug Salbutamol. The LABHALER™ inhalation technology platform consists
of a disposable single dose device powder technology and related low-cost manufacturing technology.
The LABHALER™ promises to enable highly reliable and efficient delivery of active drugs into patients’
TAIFUN® inhaler lungs in a wide range of clinical and environmental difficult conditions.
LABHALER™
focused on: real integration
LAB is an integrated drug development company.
LAB Research, provides services globally from facilities in Laval (QC,
Canada), Copenhagen (Denmark), Veszprém (Hungary), San Diego
(CA, USA). Our drug development activities are concentrated in
Turku, Finland and Laval, Canada.
Contact Information
focused on: real leadership
LAB employs highly trained staff with more than 400 employees in North America
and Europe. Our experienced clinical development team has a proven track
record of delivering results to our clients. By applying this expertise to our own
products we expect better execution, minimized cost and regulatory risk, which
will result in faster, cheaper drug development and maximized market
opportunities.
• Dr. Halvor Jaeger – Chief Executive Officer
• Luc Mainville – Chief Operating Officer
• Andrew Reiter – Chief Financial Officer
• Leigh Berryman – President – LAB Research
• Taneli Jouhikainen – President – LAB Pharma
LAB International Inc.
445 Armand Frappier Blvd.
Laval, Quebec H7V 4B3
Tel.: (450) 973-2240
Fax: (450) 686-9638
Luc Mainville ext. 1206
Chief Operating Officer
[email protected]
Frédéric Dumais
Director, Communications
and investor relations
[email protected]
Analysts
Shameze Rampertab
Jennings Capital Inc.
Tel: (416) 304-2176
Georg Hochwimmer
General Research
GmbH
[email protected]
Tel.: +49 89 25004330
[email protected]
Douglas W. Loe
Versant Partners
Tel: (416) 363-5757 ext. 101
Jeffrey J. Kraws
Crystal Research
Tel.: 609-306-2274
[email protected]
[email protected]
Aaron Bennett
Westwind Partners Inc.
Tel.: 416-815-3076
[email protected]